AMRA Contributes to Regulatory Workshop Ahead of SCWD 2024 As the Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) gears up for their 17th annual international conference in Washington, DC early next month, AMRA is pleased to share that our own Dr. Jennifer Linge will be presenting during a regulatory workshop ahead of SCWD 2024 on December 6th! The invitation-only workshop, which is hosted by SCWD and includes stakeholders from industry and regulatory agencies such as the FDA, will foster conversation around muscle wasting in weight loss therapy, with AMRA presenting on the various challenges associated with analyzing body composition to understand incretin-based therapies and muscle loss. AMRA is proud to be given a seat at the table and is looking forward to exchanging crucial knowledge with other leaders in the field that will help move disease research in this area forward. Reach out to info@amramedical.com if you want to learn more about how our unique fat and muscle composition assessments are transforming research in sarcopenia and beyond. Stay tuned for more about AMRA’s presence at #SCWD2024, and make sure to connect with the team in DC this December if you’re attending the conference. We hope to see you there! #AMRAMedical #ClinicalTrials #SCWD2024 #Sarcopenia #MuscleComposition #WeightLoss #obesity #Beyondweightloss #metabolicdisease #GLP1s #precisionmedicine #MRI
AMRA Medical’s Post
More Relevant Posts
-
Our Phase 2b ASPIRE Study is designed to provide a clear and robust comparison between our novel senolytic candidate #UBX1325 and the standard of care aflibercept. The study is now enrolling adults who struggle with vision impairment due to diabetic macular edema (#DME). Learn more about the ASPIRE Study: https://bit.ly/3RxZMRX
To view or add a comment, sign in
-
Catch up on the latest LAAC Club Module titled 'LAAC in Post-Ablation Patients: Tailoring Stroke Prevention Following the OPTION Trial Results' 👉 https://ow.ly/2Jla50Uo5aL Leading experts Prof Eloi Marijon, MD, Prof Marek Grygier, Dr Melanie Gunawardene and Dr Francesco Tomassini share their approaches to managing non-valvular atrial fibrillation (NVAF) using ablation and left atrial appendage closure (LAAC) therapy🫀 Highlights include: ✅ Insights from the OPTION Clinical Trial ✅ Stroke prevention strategies for post-ablation care ✅ Practical tips for optimising outcomes #LAAC #StrokePrevention #CardioEd #EPeeps
To view or add a comment, sign in
-
Almost 1 in 3 adults in England live with an MSK Condition, yet, almost 1 in 4 ICBs have no MSK priorities. ARMA's (the Arthritis and Musculoskeletal Alliance) new report, launched on Monday and focuses on Integrated Care Boards (ICBs) in England. 📊 MSK conditions are one of the leading causes of long-term absence from work, yet the report shows many ICBs are not giving MSK issues the attention they require. To learn more about ARMA's efforts to address #MSKInequalities read the full report here: https://ow.ly/vo9Q50Tgrzw. #HealthInequalities #ARMA #MSKConditions #PsoriaticArthritis #MSK
To view or add a comment, sign in
-
Sharing long term outcomes of RET Libretto001 trial in #lungcancer showing that there is a good track record of safety and managable AEs like HTN and LFT increases wiht selpercatinib. Good news for our patients https://lnkd.in/eNSaGsZU #MemorialCancerInstitute #MemorialHealthcareSystem #LCSM
To view or add a comment, sign in
-
Spotlight on: Prolonging #Remission In Patients With #AML 🗞️🩸 Learn more about: 🌟 Novel #transplant strategies, and reducing the risk of #relapse, Charlie Craddock 🌟 #VENTOGRAFT trial: AZA, VEN, and DLI in patients with #MDS and #AML who have relapsed following #alloSCT, Thomas Cluzeau 🌟 #Gilteritinib as post-#transplant maintenance therapy in #FLT3-ITD #AML, Mark Levis 🌟 Approaching patients with #MDS and #AML who relapse after #alloSCT & strategies to prevent #relapse, Pramila K. Take a look 👉 https://lnkd.in/eNm-pa2h #VJHemOnc #Leusm
To view or add a comment, sign in
-
ASH Daily Updates Are Live! Stay informed with daily insights from ASH 2024 from the iCMLf. We’re bringing you highlights from the conference with a summary of CML sessions. 🔍 Today, we’re highlighting key takeaways from the oral session on “Novel molecules in clinical practice.” Highlights include: - Asciminib: Exceptional efficacy and tolerability in newly diagnosed CML, with long-term benefits and fewer adverse events. - TGRX-678: A promising new option for resistant CML, showing high response rates and manageable safety profiles. - Ponatinib induction to Imatinib maintenance: A potential path to treatment-free remission with strong response retention and reduced cardiovascular risks. 📖 Read more: https://buff.ly/3ZqEtEp #ASH24 #CML #iCMLf
To view or add a comment, sign in
-
Spotlight on: Prolonging #Remission In Patients With #AML 🗞️🩸 Learn more about: 🌟 Novel #transplant strategies, and reducing the risk of #relapse, Charlie Craddock 🌟 #VENTOGRAFT trial: AZA, VEN, and DLI in patients with #MDS and #AML who have relapsed following #alloSCT, Thomas Cluzeau 🌟 #Gilteritinib as post-#transplant maintenance therapy in #FLT3-ITD #AML, Mark Levis 🌟 Approaching patients with #MDS and #AML who relapse after #alloSCT & strategies to prevent #relapse, Pramila Krishnamurthy Take a look 👉 https://lnkd.in/eNm-pa2h #VJHemOnc #Leusm
To view or add a comment, sign in
-
Spotlight on: Prolonging #Remission In Patients With #AML 🗞️🩸 Learn more about: 🌟 Novel #transplant strategies, and reducing the risk of #relapse, Charlie Craddock 🌟 #VENTOGRAFT trial: AZA, VEN, and DLI in patients with #MDS and #AML who have relapsed following #alloSCT, Thomas Cluzeau 🌟 #Gilteritinib as post-#transplant maintenance therapy in #FLT3-ITD #AML, Mark Levis 🌟 Approaching patients with #MDS and #AML who relapse after #alloSCT & strategies to prevent #relapse, Pramila Krishnamurthy Take a look 👉 https://lnkd.in/eNm-pa2h #VJHemOnc #Leusm
To view or add a comment, sign in
-
On World Lung Day we want to make sure you don't miss out on these upcoming PF Warriors educational meetings! 🗓️ Thursday, September 26th ⏱️ 10 am CT Warrior to Warrior: Open Q&A Session 🗓️ Friday, September 27th ⏱️ 10 am CT Guerreros de Fibrosis Pulmonar: Rehabilitación Pulmonar 🗓️ Monday, September 30th ⏱️ 10 am CT Special Clinical Trial Meeting: BEACON-IPF Learn more! https://lnkd.in/gpvWXwvf * Pulmonary fibrosis is a progressive lung disorder characterized by the formation of scar tissue in the lungs. This scarring leads to breathing difficulties, diminished lung function, and lower oxygen levels in the bloodstream. #PFMonth #PFWarriors #GuerrerorsdeFibrosisPulmonar
To view or add a comment, sign in
-
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia https://lnkd.in/gr9WnK8N
To view or add a comment, sign in
3,488 followers